Substance Use in Pregnancy and its Association With Cardiovascular Events
Abstract Background: Substance use and cardiovascular (CV) events are increasing among pregnant women in the United States, but association between…
cardiovascular disease
Associations Between Monthly Cannabis Use and Myocardial Infarction in Middle-Aged Adults: NHANES 2009 to 2018
Abstract Mechanistic research suggests using Cannabis sativa L. (cannabis or marijuana) may increase the risk of cardiometabolic disease, but observational…
To Weed or Not to Weed: A Systematic Review Exploring the Potential for Cannabis Use in Cardiovascular Disease, Mental Health and Pain Management
Abstract Despite its historical reputation as a substance of abuse, cannabis use has increased following decriminalization efforts in the United…
Approved Nanomedicine against Diseases
Abstract Nanomedicine is a branch of medicine using nanotechnology to prevent and treat diseases. Nanotechnology represents one of the most…
How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases
Abstract Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients…
Cannabis-induced myocardial infarction in a 27-year-old man: Case report
Abstract Cannabis smoking has been reported as one of the risk factors for coronary heart disease, which can trigger in…
Congenital anomaly epidemiological correlates of Δ8THC across USA 2003–16: panel regression and causal inferential study
Abstract Δ8-Tetrahydrocannabinol (Δ8THC) is marketed in many US states as ‘legal weed’. Concerns exist relating to class-wide genotoxic cannabinoid effects.…
Acute Cannabigerol Administration Lowers Blood Pressure in Mice
Abstract Cannabigerol is a cannabinoid compound synthesized by Cannabis sativa, which in its acid form acts as the substrate for…
Trends of Substance Use among Individuals with Cardiovascular Disease in the United States, 2015–2019
Abstract Despite the adverse effects of substance use on health among individuals with preexisting cardiovascular disease (CVD), little is known…
Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement
Abstract HFrEF is a debilitating disease with substantial morbidity, mortality, and costs. SGLT2i reduce adverse cardiovascular (including HF) and renal…